bit.bio

Where: E6/E13

bit.bio is an award-winning human synthetic biology enterprise. bit.bio's mission is to code cells for novel cures. Our vision is biomedical innovation and a new generation of cures through precision engineered human cells.

bit.bio was founded out of CEO Mark Kotter’s laboratories at Cambridge University in 2016. Based on a unique approach to biology and the foundational capabilities to precisely reprogram human cells, bit.bio is poised to become a cornerstone in the upcoming regenerative medicine revolution. With just one cell type we are seeing a revolution in cancer care.

bit.bio is working to generalise this precision cellular reprogramming approach across the whole human cell type spectrum. The possibilities for research, drug discovery and novel cures for patients are endless. With a revolutionary range of definitive, coded cells - precision-engineered human iPSC-derived cells driven with our unique opti-ox™ technology that offer speed, reliability and consistency at scale for research and drug discovery.

"At bit.bio, we are passionate about engineering human cells that will enable the medicine of the future." Mark Kotter | MD, PhD, Founder | CEO